| Species authentication of common meat based on PCR analysis of the mitochondrial COI gene Z Dai, J Qiao, S Yang, S Hu, J Zuo, W Zhu, C Huang Applied biochemistry and biotechnology 176, 1770-1780, 2015 | 45 | 2015 |
| The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains Z Dai, W Mu, Y Zhao, X Jia, J Liu, Q Wei, T Tan, J Zhou Molecular Therapy 29 (9), 2707-2722, 2021 | 31 | 2021 |
| T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape Z Dai, W Mu, Y Zhao, J Cheng, H Lin, K Ouyang, X Jia, J Liu, Q Wei, ... Signal transduction and targeted therapy 7 (1), 85, 2022 | 30 | 2022 |
| Clinical and immunological features of platelet transfusion refractoriness in young patients with de novo acute myeloid leukemia X Hu, H Cai, L Zheng, Y Luo, J Zhou, Y Hui, Z Dai, H Lin, D Li, Y Xiao, ... Cancer Medicine 9 (14), 4941-4948, 2020 | 14 | 2020 |
| B7H6 serves as a negative prognostic marker and an immune modulator in human pancreatic cancer Z Zhu, KY Teng, J Zhou, Y Xu, L Zhang, H Zhao, X Zhang, L Tian, Z Li, ... Frontiers in Oncology 12, 814312, 2022 | 7 | 2022 |
| Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia J Cheng, T Ge, X Zhu, J Wang, Y Zeng, W Mu, H Cai, Z Dai, J Jin, Y Yang, ... Cancer Immunology, Immunotherapy 72 (7), 2331-2346, 2023 | 5 | 2023 |
| Development and functional characterization of novel fully human anti‐CD19 chimeric antigen receptors for T‐cell therapy Z Dai, X Hu, X Jia, J Liu, Y Yang, P Niu, G Hu, T Tan, J Zhou Journal of Cellular Physiology 236 (8), 5832-5847, 2021 | 2 | 2021 |
| Cd5-targeting fully humanized antibody T Tan, Q Wei, X Jia, J Tan, M Xie, DAI Zhenyu US Patent App. 18/261,059, 2024 | | 2024 |
| Fully human single-domain tandem chimeric antigen receptor (car) targeting cd5, and use thereof T Tan, DAI Zhenyu, J Zhou, Y Zhao, Q Wei, X Jia, J Liu US Patent App. 18/261,067, 2024 | | 2024 |
| Fully human antibody targeting cd5, and fully human chimeric antigen receptor (car) and application thereof T Tan, DAI Zhenyu, J Zhou, Q Wei, X Jia, Y Zhao, M Xie US Patent App. 18/251,294, 2024 | | 2024 |
| Antibody and chimeric antigen receptor (car) binding to cd70, and application thereof Y Yongkun, G Hu, NIU Panpan, M Guangrong, J Mo, J Zhang, Q Hu, ... US Patent App. 18/248,771, 2023 | | 2023 |
| Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma W Mu, M Zhang, G Hu, Y Han, X Mao, C Chen, K Shen, Z Dai, X Zhu, ... Frontiers in Immunology 14, 1280007, 2023 | | 2023 |
| Fully humanized bispecific chimeric antigen receptor targeting cd19 and cd22 and use thereof Y Yongkun, G Hu, T Tan, DAI Zhenyu, NIU Panpan, M Guangrong, ... US Patent App. 18/002,714, 2023 | | 2023 |
| Fully human single-domain tandem chimeric antigen receptor (CAR) targeting CD5, and use thereof TAN Taochao, DAI Zhenyu, Z Jianfeng, Z Ya, WEI Qiaoe, JIA Xiangyin, ... WO Patent WO/2022/152186 A1, 2022 | | 2022 |
| CD5-targeting fully humanized antibody TAN Taochao, WEI Qiaoe, JIA Xiangyin, TAN Jiayue, XIE Meng, DAI Zhenyu WO Patent WO/2022/152185 A1, 2022 | | 2022 |
| Fully human antibody targeting cd19 and application thereof T Tan, DAI Zhenyu, X Jia, Q Wei, Y Yongkun US Patent App. 17/613,367, 2022 | | 2022 |
| CT120, a novel fully human anti-CD19 x anti-CD22 dual targeted chimeric antigen receptor T cell product for the treatment of B-NHL and B-ALL P Niu, Q Hu, J Mo, G Meng, X Jia, W Cheng, Q Wei, Z Dai, X Wu, G Hu, ... Cancer Research 82 (12_Supplement), 2811-2811, 2022 | | 2022 |
| Antibody and chimeric antigen receptor (car) binding to cd70, and application thereof YANG Yongkun, HU Guang, NIU Panpan, MENG Guangrong, MO Jialu, ZHANG Jianhua ... WO Patent WO/2022/078344 A1, 2022 | | 2022 |
| Fully humanized bispecific chimeric antigen receptor targeting cd19 and cd22 and use thereof YANG Yongkun, HU Guang, TAN Taochao, DAI Zhenyu, NIU Panpan, MENG Guangrong ... WO Patent WO/2022/002154 A1, 2022 | | 2022 |
